news
Pfizer and Samsung Biologics ink biosimilars manufacturing deal
Samsung Biologics has signed two long-term manufacturing agreements for Pfizer’s multiproduct biosimilar portfolio, worth $897 million.
List view / Grid view
Contract Manufacturing
article
The cell and gene therapy CDMO bottleneck isn’t capacity – it’s capability
CDMOs have been squeezed by the sharp increase in companies preparing to scale their cell and gene therapy manufacturing for Phase III trials and commercialisation, and physical capacity has been a common scapegoat. But eXmoor CEO Angela Osborne says the real limiting factor is experience.
news
CGT supply chain and logistics market worth $3.12b by 2031
Improvements in real-time supply chain operations is expected to drive the cell and gene therapy supply chain/logistics market, a report says.
news
Collaboration to produce 3D screen printed pharmaceuticals
A new collaboration between two industry players for cGMP production of 3D screen printing technologies could reduce drug development costs.
news
Pharmapack Europe to launch two new zones in 2024
Two new zones will be launched at Pharmapack Europe in 2024, to support growing demand for biologics, mRNA therapeutics and contract packaging.
news
WuXi STA opens its first oral solids continuous manufacturing line
Operation has begun for CRDMO WuXi STA's first continuous manufacturing line for oral solids, in Wuxi city, China.
news
Catalent opens one of largest cell therapy manufacturing facilities in the world
Sited in Belgium, Catalent has opened one of the largest commercial-scale cell therapy manufacturing facilities in the world.
news
CPHI report predicts huge funding overhang to drive contract services growth
Private equity overhang to fuel CDMO valuations and expansions, while venture capital overhang will fuel continued demand for services in spite of adverse global conditions.
news
CPHI report predicts biologics outsourcing to surge in 2023
Report out ahead of CPHI Frankfurt predicts ‘biologics outsourcing to surge in 2023, as China’s innovation engine stalls.'
news
Evaluating benefits of outsourcing biopharma R&D
Near-term gains from outsourcing biopharma R&D activities can be offset by slower innovation in the long run, according to a recent paper.
news
HPAPI contract manufacturing to value $14.6 billion by 2030
Rising demand for cancer drugs, combined with high in-house manufacturing costs is driving growth in the high-potency API outsourcing market.
news
Sanofi to sell Japanese manufacturing plant
Sanofi’s Japan-based manufacturing site near Tokyo will be sold to a European contract development and manufacturing organisation.
news
OSD contract manufacturing market valued at $54.7 billion by 2030
Outsourcing the production of oral solids is estimated to be the primary influencer for the contract manufacturing market in the next decade, using lessons learnt from the COVID-19 pandemic.
news
Trends in biopharma contract manufacturing 2022
As biopharmaceuticals become an increasingly important part of the drug development pipeline and market, EPR discusses key trends in the outsourcing of their manufacturing.
news
Pharma contract manufacturing market to grow to $130bn by 2026
Growth in the global pharmaceutical contract manufacturing market will be driven by rising consumption of medicines and increasing commercialisation of generic and innovative therapies, among other factors.
